Nalfurafine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Nalfurafine (INN and USAN;[1] also known as AC-820, TRK-820; trade name Remitch) is a κ-opioid receptor agonist marketed as a treatment for uremic pruritus in people undergoing hemodialysis.[2]
As of January 2010, it is also being investigated for the treatment of pruritus in patients with chronic liver disease.[3]
References
- ↑ Statement on a Nonproprietary Name adopted by the USAN Council
- ↑ “AC-820”. Acologix. 2009.
- ↑ Clinical trial number NCT00638495 for “Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease” at ClinicalTrials.gov
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH